The Nanofacturing consortium has worked on a pan-European nanopharmaceutical project to develop new manufacturing methods and improve supply chain co-ordination to advance treatments for rare cancers, autoimmune diseases and viral infections. The Nanofacturing collaboration has accelerated the development of nanotechnologies with the goal of bringing more targeted and effective therapies to market.
For more information see the IDTechEx report on Biobased Polymers 2018-2023. Specifically, the eight-partner project has centred upon the processing of glycan-coated gold nanoparticles, which have the ability to circulate freely in the blood and, with the addition of targeting ligands, to preferentially enter diseased cells or antigen-processing cells of the immune system.
These small nanoparticles, to which therapeutic drugs or immunotherapeutic peptides can be attached, can pass across blood vessels to deliver medicine directly to diseased sites before being excreted from the body.
Areitio Junquera, Project Co-Ordinator from Midatech Pharma, said:
“This rapidly emerging technology has the potential to deliver drugs more effectively and in a kinder way to patients. Preclinical studies have demonstrated how highly toxic, anti-cancer drugs can be specifically targeted to tumour cells while sparing normal tissue, and how antigenic peptides can be delivered with improved potency to the immune system. Over the course of the project, clinical grade gold nanoparticle treatments have been manufactured and are now being investigated in clinical trials.”
Nanocarriers, which include glycan-coated gold nanoparticles, are forecast to account for 40 per cent of a $136 billion nanotechnology-enabled drug delivery market by 2021(1). However, their development has previously suffered from a number of challenges, with scale-up of production from pre-clinical, laboratory scale to clinical testing hampered by a lack of pilot manufacturing capacity and supply chain infrastructure. High development costs have also prevented SMEs from taking gold nanoparticle drug programs to commercialisation.
News This Week
Within a day of testing positive for covid-19 in June, Miranda Kelly was sick enough to be scared. At 44, with diabetes and high blood pressure, Kelly, a certified nursing assistant, was having trouble [...]
A technology developed at Vanderbilt University Medical Center has led to the discovery of an "ultra-potent" monoclonal antibody against multiple variants of SARS-CoV-2, the virus responsible for COVID-19, including the delta variant. The antibody [...]
Research has found a significant fall in levels of antibodies against SARS-CoV-2, the virus that causes COVID-19, 6 months after the second dose of the Pfizer-BioNTech vaccine. Clinical evidence also suggests that the risk [...]
Are the COVID vaccines substantially different from/inferior to other vaccines in terms of their effectiveness? The issue raised, and I'm mostly paraphrasing here, is this: Most vaccines (e.g. measles, smallpox) have efficacy defined such [...]
The EVONANO platform allows scientists to grow virtual tumors and use artificial intelligence to automatically optimize the design of nanoparticles to treat them. The ability to grow and treat virtual tumors is an [...]
Modern Approaches to Augmentation of Brain Function Available from Springer Press This book covers recent advances in neural technology that provide for enhancements for brain function. It addresses a broad range of neural phenomena [...]
Although the currently available COVID-19 vaccines are highly effective, limited manufacturing capacity and the need for cold-chain storage hinder their global distribution. A recent study tested the efficacy of a new adeno-associated virus (AAV) [...]
Fully vaccinated people were 11 times less likely to die of COVID and 10 times less likely to be hospitalized compared to the unvaccinated since highly contagious Delta became the most common variant, US [...]
The highly-infectious Delta coronavirus variant has spread to at least 174 countries worldwide, from the US to Australia, causing a surge in COVID-19 cases. The variant has mutations that help it partially escape the immune response produced by [...]
Fragile mRNA molecules used in COVID-19 vaccines can’t get into cells on their own. They owe their success to lipid nanoparticles that took decades to refine. Messenger RNA (mRNA) is having a moment. This [...]
The COVID-19 pandemic has revealed critical knowledge gaps and assumptions concerning how respiratory viruses spread between hosts. Traditionally thought to be spread mainly through large respiratory droplets produced by the coughs and sneezes of sick individuals, [...]
SARS-CoV-2 is just one of nonillions of viruses on our planet, and scientists are rapidly identifying legions of new species. Mya Breitbart has hunted novel viruses in African termite mounds, Antarctic seals and water [...]
As a team of South African researchers we have identified a new lineage of SARS-CoV-2, the virus causing COVID-19. A lineage represents a genetically distinct virus population with a common ancestor. This virus may be designated as a variant [...]